---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-010140"
form_type: "8-K"
ticker: "MIRA"
cik: "0001904286"
company_name: "MIRA PHARMACEUTICALS, INC."
filed_at: "2025-03-13T23:59:59+00:00"
generated_at: "2026-05-24T21:39:08.862118+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Mira Pharmaceuticals develops topical Ketamir-2 for localized pain; preclinical study underway

## Summary
- Topical Ketamir-2 designed for slow release, enabling targeted pain relief with minimal systemic exposure.
- Preclinical study assessing efficacy of topical formulation against inflammatory pain is ongoing.
- Phase 1 oral trial for Ketamir-2 continues; Phase 2a in diabetic neuropathy planned by year-end 2025.
- First human efficacy data from Phase 2a expected in Q1 2026.

## SEC filing metadata
- accession: 0001493152-25-010140
- form_type: 8-K
- ticker: MIRA
- cik: 0001904286
- company_name: MIRA PHARMACEUTICALS, INC.
- filed_at: 2025-03-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1904286/000149315225010140/0001493152-25-010140-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1904286/000149315225010140/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-010140
- JSON: https://secwatch.observer/filing/0001493152-25-010140.json
- Plain text: https://secwatch.observer/filing/0001493152-25-010140.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.